AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest
Swedish Biotech Is Developing Broad CNS portfolio
Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.
You may also be interested in...
While a so-called disease modifying treatment has entered the market for the first time, in the form of Biogen’s Aduhelm, Alzheimer’s disease is unlikely to be cured by one drug alone. In Vivo explores the array of approaches to AD drug development, drawing on interviews with industry leaders and pipeline data.
Biogen/Eisai’s Alzheimer’s drug aducanumab could face difficulties with health technology appraisal institutes should it win approval in the EU.
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.